Finding the "killer app" for treating obese individuals has seen no shortage of efforts result in failure over the years. The slow start of VIVUS' Qsymia has investors doubting the market potential of both it and Arena Pharmaceuticals' new drugs targeting the problem. In the following video, health care bureau chief Brenton Flynn runs through yet another example of a novel obesity treatment approach that seems destined for failure from EnteroMedics
Will anyone win the war on obesity?
With EnteroMedics seemingly out of the picture, can VIVUS pick up its lagging sales, or will Arena Pharmaceuticals reign supreme in the obesity space? If you're in the dark, grab copies of The Motley Fool's premium research reports on VIVUS and Arena Pharmaceuticals to stay up to date. Senior biotech analyst Brian Orelli gives investors the must-know information, including an in-depth look at the obesity market and reasons to buy and sell both stocks. Click now for an exclusive look at Arena and VIVUS -- complete with a full year of free updates -- today.
The article An Obesity Treatment Doomed for Failure? originally appeared on Fool.com.
Brenton Flynn has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.